Literature DB >> 9923658

A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren's syndrome contain increased latent and active gelatinase-B levels.

R Hanemaaijer1, H Visser, Y T Konttinen, P Koolwijk, J H Verheijen.   

Abstract

Here we describe a new principle for accessing the activity of the different members of the human matrix-metalloproteinases (MMPs) by a colorimetric assay. Using protein engineering, a modified pro-urokinase was made in which the activation sequence, normally recognized by plasmin (ProArgPheLys/IleIleGlyGly), was replaced by a sequence that is specifically recognized by MMPs (ArgProLeuGly/IleIleGlyGly). The active urokinase resulting from the activation of this modified pro-urokinase by MMPs can be measured directly using a chromogenic peptide substrate for urokinase. The assay has been made specific for MMP-9 using an MMP-9 specific monoclonal antibody. Using this antibody MMP-9 is captured from biological fluids or tissue culture media, and MMP-activity of both active and latent MMP-9 can be analysed. We determined the gelatinase-B (MMP-9) activity present in saliva from patients with Sjögren's syndrome. Using a general gelatinase assay with radioactively-labeled gelatinated collagen it was observed that gelatinase activity was slightly, though not significantly, increased in patients: general gelatinase activity in patients versus healthy controls: 17.0 +/- 4.9 vs 12.2 +/- 2.5 x 10(4) cpm/ml (p > 0.05, and 44.0 (4.0 vs 36.1 +/- 1.9 x 10(4) cpm/ml (p > 0.05), for active and latent gelatinase, respectively. However, using the immunocapture activity assay (using modified urokinase) specifically MMP-9 activity was measured, which was significantly increased in saliva from patients compared to healthy controls: MMP-9 (already active): patients 8.9 +/- 2.5 U/mg, controls 1.0 +/- 0.5 U/mg (p = 0.002); latent plus active MMP-9: patients 53.1 +/- 9.8 U/mg, controls 16.5 +/- 2.6 U/mg (p = 0.01). This assay, measuring MMP-9 activity using modified pro-urokinase as a substrate can easily be adapted for the specific detection of the various members of the MMP-family or other difficult to measure proteases, in a format that can be used for high throughput screening of compounds or samples.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9923658     DOI: 10.1016/s0945-053x(98)90116-0

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  20 in total

1.  Basal lamina disorganisation of the acini and ducts of labial salivary glands from patients with Sjogren's syndrome: association with mononuclear cell infiltration.

Authors:  C Molina; C Alliende; S Aguilera; Y-J Kwon; L Leyton; B Martínez; C Leyton; P Pérez; M-J González
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

2.  Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes.

Authors:  Ian B McKittrick; Yolanda Bogaert; Kristen Nadeau; Janet Snell-Bergeon; Amber Hull; Tao Jiang; Xiaoxin Wang; Moshe Levi; Karen S Moulton
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

Review 3.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

4.  Correlation between the matrix metalloproteinase-9 activity and chondroitin sulfate concentrations in tear fluid after laser in situ keratomileusis.

Authors:  Tetsuya Mutoh; Masaya Nishio; Yukihiro Matsumoto; Kiyomi Arai
Journal:  Clin Ophthalmol       Date:  2010-07-30

5.  A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour.

Authors:  A H G Hansma; Y van Hensbergen; B C Kuenen; P J van Diest; R Hanemaaijer; S Meijer; H M Pinedo; K Hoekman
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

6.  Cathepsin K is the principal protease in giant cell tumor of bone.

Authors:  Jan H N Lindeman; Roeland Hanemaaijer; Adri Mulder; P D Sander Dijkstra; Károly Szuhai; Dieter Bromme; Jan H Verheijen; Pancras C W Hogendoorn
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

7.  Persisting high levels of synovial fluid markers after cartilage repair: a pilot study.

Authors:  Anna I Vasara; Yrjö T Konttinen; Lars Peterson; Anders Lindahl; Ilkka Kiviranta
Journal:  Clin Orthop Relat Res       Date:  2008-08-15       Impact factor: 4.176

8.  Mapping Salivary Proteases in Sjögren's Syndrome Patients Reveals Overexpression of Dipeptidyl Peptidase-4/CD26.

Authors:  Laís Garreto; Sébastien Charneau; Samuel Coelho Mandacaru; Otávio T Nóbrega; Flávia N Motta; Carla N de Araújo; Audrey C Tonet; Flávia M B Modesto; Lilian M Paula; Marcelo Valle de Sousa; Jaime M Santana; Ana Carolina Acevedo; Izabela M D Bastos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

9.  Identification of free nitric oxide radicals in rat bone marrow: implications for progenitor cell mobilization in hypertension.

Authors:  Marina A Aleksinskaya; Ernst E H van Faassen; Jelly Nelissen; Ben J A Janssen; Jo G R De Mey; Roeland Hanemaaijer; Ton Rabelink; Anton Jan van Zonneveld
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

10.  Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke.

Authors:  Kimberly E Hawkins; Kelly M DeMars; Changjun Yang; Gary A Rosenberg; Eduardo Candelario-Jalil
Journal:  Mol Brain       Date:  2013-03-23       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.